These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma. Glinghammar B; Berg AL; Bjurström S; Stockling K; Blomgren B; Westerberg R; Skånberg I; Hellmold H; Andersson U Toxicol Pathol; 2011 Feb; 39(2):325-36. PubMed ID: 21270424 [TBL] [Abstract][Full Text] [Related]
11. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Chira EC; McMillen TS; Wang S; Haw A; O'Brien KD; Wight TN; Chait A Atherosclerosis; 2007 Nov; 195(1):100-9. PubMed ID: 17214992 [TBL] [Abstract][Full Text] [Related]
12. PPAR Agonists: II. Fenofibrate and Tesaglitazar Alter Behaviors Related to Voluntary Alcohol Consumption. Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA Alcohol Clin Exp Res; 2016 Mar; 40(3):563-71. PubMed ID: 26857541 [TBL] [Abstract][Full Text] [Related]
13. PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. Ferguson LB; Most D; Blednov YA; Harris RA Neuropharmacology; 2014 Nov; 86():397-407. PubMed ID: 25036611 [TBL] [Abstract][Full Text] [Related]
14. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874 [TBL] [Abstract][Full Text] [Related]
15. Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro. Stefanick JF; Omstead DT; Ashley JD; Deak PE; Mustafaoglu N; Kiziltepe T; Bilgicer B J Control Release; 2019 Oct; 311-312():190-200. PubMed ID: 31473250 [TBL] [Abstract][Full Text] [Related]
16. Tesaglitazar: a promising approach in type 2 diabetes. Cox SL Drugs Today (Barc); 2006 Mar; 42(3):139-46. PubMed ID: 16628256 [TBL] [Abstract][Full Text] [Related]
17. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970 [TBL] [Abstract][Full Text] [Related]
18. Deficiency in Nrf2 transcription factor decreases adipose tissue mass and hepatic lipid accumulation in leptin-deficient mice. Xu J; Donepudi AC; More VR; Kulkarni SR; Li L; Guo L; Yan B; Chatterjee T; Weintraub N; Slitt AL Obesity (Silver Spring); 2015 Feb; 23(2):335-44. PubMed ID: 25451536 [TBL] [Abstract][Full Text] [Related]
19. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity. Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852 [TBL] [Abstract][Full Text] [Related]
20. PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice. Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA Alcohol Clin Exp Res; 2016 Mar; 40(3):553-62. PubMed ID: 26857685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]